Live webinar from Singapore: Portfolio analysis - Choosing your communication strategy
Tuesday 1st October 2019 16:00SGT/ 16:00CST/ 17:00JST
Portfolio Analysis and Optimization concentrates on determining the impact that multiple assets have within therapeutic categories, and how the marketing of these assets impacts on overall strategy. This is an important tool for pharmaceutical companies in today’s market. As they simultaneously develop multiple products that can become extremely costly, portfolio management to improve decision-making can have a significant impact on the bottom line. At its very core, it is about selecting how to allocate resources and marketing efforts across multiple assets.
How to conduct an effective epidemiological data review
Clients often ask us if we can triangulate various data sources to fully understand the opportunity for an asset. There are clear benefits - combining primary market research findings with existing data sets provides validity and depth, whilst eliminating many inconsistencies, which helps guide the direction for future marketing strategy and initiatives.
Richard Head presented with MR Excellence award at EphMRA Conference
We were delighted to exhibit, sponsor and present three papers at the EphMRA conference where Director Richard Head was presented with the runner-up award for ‘Business Impact through Innovation’.
Along with Richard Head, Director Paula Coyle and Associate Directors Emilie Braund and An-hwa Lee represented Research Partnership at the three-day annual event, which this year took place at the Hilton Hotel and Convention Centre in Warsaw, Poland.
How patient insights were brought to life with graphic novel outputs
Our client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks. Their new product promised greater freedom from these acute attacks and therefore from the associated burden. The challenge was to understand why many patients remain on older therapy types and how the pathway to more modern therapy options, with better efficacy and side effect profiles, could be mapped out for physicians and patients. Our client further requested that insights from the research were brought to life in the insights workshop meeting in a new and impactful way.
Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?
China has long been a magnet for pharmaceutical multinationals looking to offset flattening growth in established markets
It offers rapid economic development, a population of around 1.4 billion with limited access to cutting-edge medicine, and changing lifestyles that have raised health expectations. Expanded access to state-funded healthcare, population aging and a growing burden of chronic disease are creating new opportunities for innovative drugs alongside low-cost generics.